IL157541A0 - METHOD FOR PROTECTING CELLS AND TISSUES FORM IONIZING RADIATION TOXICITY WITH alpha, beta UNSATURATED ARYL SULFONES - Google Patents

METHOD FOR PROTECTING CELLS AND TISSUES FORM IONIZING RADIATION TOXICITY WITH alpha, beta UNSATURATED ARYL SULFONES

Info

Publication number
IL157541A0
IL157541A0 IL15754102A IL15754102A IL157541A0 IL 157541 A0 IL157541 A0 IL 157541A0 IL 15754102 A IL15754102 A IL 15754102A IL 15754102 A IL15754102 A IL 15754102A IL 157541 A0 IL157541 A0 IL 157541A0
Authority
IL
Israel
Prior art keywords
alpha
beta unsaturated
unsaturated aryl
ionizing radiation
radiation
Prior art date
Application number
IL15754102A
Other languages
English (en)
Original Assignee
Univ Temple
Onconova Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple, Onconova Therapeutics Inc filed Critical Univ Temple
Publication of IL157541A0 publication Critical patent/IL157541A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL15754102A 2001-02-28 2002-02-28 METHOD FOR PROTECTING CELLS AND TISSUES FORM IONIZING RADIATION TOXICITY WITH alpha, beta UNSATURATED ARYL SULFONES IL157541A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27199001P 2001-02-28 2001-02-28
PCT/US2002/006107 WO2002069892A2 (en) 2001-02-28 2002-02-28 METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH α, β UNSATURATED ARYL SULFONES

Publications (1)

Publication Number Publication Date
IL157541A0 true IL157541A0 (en) 2004-03-28

Family

ID=23037934

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15754102A IL157541A0 (en) 2001-02-28 2002-02-28 METHOD FOR PROTECTING CELLS AND TISSUES FORM IONIZING RADIATION TOXICITY WITH alpha, beta UNSATURATED ARYL SULFONES
IL157541A IL157541A (en) 2001-02-28 2003-08-21 Use of alpha, beta unsaturated aryl sulfone compounds for preparing radioprotective compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL157541A IL157541A (en) 2001-02-28 2003-08-21 Use of alpha, beta unsaturated aryl sulfone compounds for preparing radioprotective compositions

Country Status (10)

Country Link
US (1) US6667346B2 (https=)
EP (1) EP1370253B8 (https=)
JP (1) JP4302986B2 (https=)
KR (1) KR100850331B1 (https=)
AT (1) ATE406881T1 (https=)
AU (1) AU2002305942B2 (https=)
CA (1) CA2439288C (https=)
DE (1) DE60228692D1 (https=)
IL (2) IL157541A0 (https=)
WO (1) WO2002069892A2 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028828A1 (en) 2000-10-05 2002-04-11 Temple University - Of The Commonwealth System Of Higher Education Substituted (e)-styryl benzylsulfones for treating proliferative disorders
EP1534284B1 (en) * 2002-02-28 2011-07-27 Temple University - Of The Commonwealth System of Higher Education Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
WO2003072062A2 (en) * 2002-02-28 2003-09-04 Temple University-Of The Commonwealth System Of Higher Education Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
JP5196787B2 (ja) * 2003-11-14 2013-05-15 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 増殖性疾患を治療するためのα，β−不飽和スルホキシド
US7649013B2 (en) * 2003-11-26 2010-01-19 Arqule, Inc. Methods of protecting against radiation injury
KR101274524B1 (ko) 2004-03-16 2013-06-19 온코노바 테라퓨틱스, 인코포레이티드 증식성 질병 치료용 치환 페녹시- 및 페닐티오- 유도체
EP1773310B9 (en) 2004-06-24 2012-04-25 Temple University - Of The Commonwealth System of Higher Education Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof
CA2574491C (en) * 2004-07-19 2011-05-24 Onconova Therapeutics, Inc. Formulations for parenteral administration of (e)-2,6-dialkoxystryryl 4-substituted benzylsulfones
US7537572B2 (en) 2004-10-22 2009-05-26 General Patent, Llc Treatment or pre-treatment for radiation/chemical exposure
US20090306207A1 (en) * 2005-01-05 2009-12-10 Reddy M V Ramana Treatment of Drug-Resistant Proliferative Disorders
AU2006216544B2 (en) * 2005-02-25 2012-04-05 Onconova Therapeutics, Inc. Unsaturated sulfides, sulfones, sulfoxides and sulfonamides synthesis
WO2006104668A2 (en) * 2005-03-11 2006-10-05 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of proliferative diseases
AU2006275822B2 (en) * 2005-07-29 2012-02-02 Onconova Therapeutics, Inc. Formulation of radioprotective alpha, beta unsaturated aryl sulfones
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
JP2007302640A (ja) * 2006-05-15 2007-11-22 Natl Inst Of Radiological Sciences 抗放射線被ばく障害剤
CA2659222C (en) * 2006-07-28 2012-01-31 Onconova Therapeutics, Inc. Formulations of radioprotective .alpha., .beta. unsaturated aryl sulfones
JP5278968B2 (ja) 2006-08-30 2013-09-04 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 骨髄異形性症候群及び急性骨髄性白血病の治療のための組成物及び方法
CA2663375A1 (en) * 2006-09-15 2008-03-20 Onconova Therapeutics, Inc. Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions
WO2008076270A2 (en) * 2006-12-13 2008-06-26 Temple University-Of The Commonwealth System Of Higher Education Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof
US20100049284A1 (en) * 2008-05-15 2010-02-25 The Catholic University Of America Use of heat to treat biological systems exposed to damaging radiation
JP2012504646A (ja) * 2008-10-01 2012-02-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護
CN102231983A (zh) * 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
JP5734869B2 (ja) * 2008-12-16 2015-06-17 オンコノバ・セラピューティックス・インコーポレーテッド ヒトにおける細胞毒性物質の有害作用に対する治療レジメンの有効性を決定する方法
JP2012526850A (ja) 2009-05-13 2012-11-01 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル サイクリン依存性キナーゼ阻害剤及びその用法
CA2792883A1 (en) * 2010-03-24 2011-09-29 Onconova Therapeutics, Inc. Compositions and methods for prevention and treatment of wounds
KR101838764B1 (ko) * 2010-03-26 2018-03-14 온코노바 테라퓨틱스, 인코포레이티드 (ｅ)-4-카복시스티릴-4-클로로벤질설폰의 개선된 안정한 수성 제형
GB201010359D0 (en) 2010-06-21 2010-08-04 Univ Nottingham Compounds for treating proliferative disorders
WO2012068381A2 (en) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
KR101992929B1 (ko) 2012-09-20 2019-06-25 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 치환된 알킬 디아릴 유도체, 제조방법 및 용도
CA2906157C (en) 2013-03-15 2022-05-17 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
ME03557B (me) 2013-03-15 2020-07-20 G1 Therapeutics Inc Privremena zaštiтa normalnih ćelija током hemoterapije
CN104230770B (zh) * 2013-06-17 2017-11-21 华夏生生药业(北京)有限公司 苯乙烯基砜类化合物、其制备方法以及其作为神经保护剂的应用
US10195466B2 (en) * 2014-01-06 2019-02-05 Hackensack University Medical Center Method for treating skin cancer using radiation therapy
WO2015161288A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
US10383831B2 (en) 2015-08-03 2019-08-20 Temple University—Of the Commonwealth System of Higher Education 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use
CN106432011B (zh) * 2016-09-18 2018-11-02 中国医学科学院放射医学研究所 一类具有辐射防护作用的新化合物、其制备方法及其药物应用
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
BR112020006677A2 (pt) 2017-10-05 2020-10-06 Fulcrum Therapeutics, Inc. uso de inibidores p38 para reduzir a expressão de dux4
JP7324930B2 (ja) * 2019-07-18 2023-08-10 フアシアシェンシェン ファーマシューティカル ベイジン カンパニー リミテッド カルバメート置換スチリルスルホン類化合物及びその製造方法ならびにその使用
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU741042B2 (en) 1997-10-03 2001-11-22 Temple University - Of The Commonwealth System Of Higher Education Styryl sulfone anticancer agents
US6201154B1 (en) * 1999-03-31 2001-03-13 Temple University-Of The Commonwealth Of Higher Education Z-styryl sulfone anticancer agents
EP1173160B1 (en) * 1999-04-02 2005-06-22 Temple University of the Commonwealth System of Higher Education (e)-styryl sulfone anticancer agents
AU3381399A (en) * 1999-04-02 2000-10-23 Temple University - Of The Commonwealth System Of Higher Education Styryl sulfone anticancer agents
AU780844B2 (en) * 1999-10-12 2005-04-21 Temple University-Of The Commonwealth System Of Higher Education Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
US7271187B2 (en) * 2000-04-06 2007-09-18 Tim Neuberger Compositions and methods for promoting tissue regeneration
US6486210B2 (en) 2000-04-14 2002-11-26 Temple University—Of the Commonwealth System of Higher Education Substituted styryl benzylsulfones for treating proliferative disorders
US6646009B2 (en) * 2001-02-28 2003-11-11 Temple University — Of Commonwealth System of Higher Education N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof

Also Published As

Publication number Publication date
EP1370253B8 (en) 2008-11-26
JP4302986B2 (ja) 2009-07-29
JP2004525908A (ja) 2004-08-26
AU2002305942B2 (en) 2006-10-26
KR100850331B1 (ko) 2008-08-04
CA2439288A1 (en) 2002-09-12
US20030060505A1 (en) 2003-03-27
EP1370253B1 (en) 2008-09-03
EP1370253A4 (en) 2005-08-17
EP1370253A2 (en) 2003-12-17
IL157541A (en) 2010-05-31
KR20030086596A (ko) 2003-11-10
DE60228692D1 (de) 2008-10-16
CA2439288C (en) 2011-08-09
US6667346B2 (en) 2003-12-23
WO2002069892A2 (en) 2002-09-12
WO2002069892A3 (en) 2002-11-07
ATE406881T1 (de) 2008-09-15

Similar Documents

Publication Publication Date Title
IL157541A0 (en) METHOD FOR PROTECTING CELLS AND TISSUES FORM IONIZING RADIATION TOXICITY WITH alpha, beta UNSATURATED ARYL SULFONES
WO2005044181A3 (en) Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
WO2005065074A3 (en) Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
Capizzi The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (ethyol®)
EA200000087A1 (ru) Повышение эффективности терапии гиперпролиферативных состояний с помощью антиоксиданта
ES2062155T3 (es) Composiciones para el tratamiento de neoplasia que contienen un agente antineoplasico y un agente protector reductor de efectos secundarios.
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
EP2295063A8 (en) Compositions and the use thereof the treatment of mitochondrial diseases
CA2402169A1 (en) Formulation and method for treating neoplasms by inhalation
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
AR011133A1 (es) MICROGRÁNULOS DE LIBERACIoN CONTROLADA QUE CONTIENEN CISPLATINO , PROCEDIMIENTO DE SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA Y UTILIZACIoN EN LA FABRICACIoN DE UN MEDICAMENTO POLIQUIMIOTERAPIA O EN ASOCIACIoN CON UNA RADIOTERAPIA.
Floersheim et al. Protection against ionising radiation and synergism with thiols by zinc aspartate
WO2005039554A3 (en) Therapeutic use of methionine for the treatment or prevention of mucositis
Anné et al. A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer
Grdina et al. Relationships between cytoprotection and mutation prevention by WR-1065
WO2008105808A3 (en) FORMULATIONS OF RADIOPROTECTIVE α, β UNSATURATED ARYL SULFONES
NZ504928A (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
IL149064A0 (en) Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
AU4338501A (en) Combination chemotherapy
WO2007038428A3 (en) Prevention and treatment of gastrointestinal and bladder disorders using active vitamin d compounds
CA2288059A1 (en) Method of treating malignancies
MD2549G2 (ro) Metodă de tratament a hepatitei virale cronice C.
MX2023005695A (es) Administracion de agonista de sting, inhibidores de puntos de control y radiacion.
TW200509909A (en) Use of organic compounds
BE1000723A4 (fr) Utilisation de gangliosides exogenes dans des maladies tumorales comme facteur de protection contre la toxicite de medicaments antitumoraux.